Intensity Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC on November 5, 2026, reporting a net loss of $3.544 million for the third quarter.

Key Highlights

  • Net loss of $3.544 million for the three months ended September 30, 2026, compared to a net loss of $2.671 million in the same period of 2025, according to the filing.
  • Nine-month net loss of $8.985 million for the period ended September 30, 2026, versus $8.555 million for the same period in 2025.
  • Cash and cash equivalents of $8.494 million as of September 30, 2026, down from $11.921 million as of December 31, 2025.
  • Total assets of $10.287 million as of September 30, 2026, compared to $14.101 million as of December 31, 2025.
  • Accumulated deficit of $87.374 million as of September 30, 2026, up from $78.389 million at year-end 2025.
  • Shares outstanding increased to 3,295,794 as of September 30, 2026, from 2,524,475 as of December 31, 2025.
  • Loss per share of $1.09 (basic and diluted) for Q3 2026, compared to $1.55 for Q3 2025.

Intensity Therapeutics Reports Higher Q3 2026 Operating Expenses and Declining Cash

According to the filing, Intensity Therapeutics (NASDAQ:INTS) reported total operating expenses of $3.623 million for the three months ended September 30, 2026, up from $2.733 million in the comparable prior-year quarter. Research and development expenses accounted for $2.429 million of that total, compared to $1.553 million in Q3 2025. General and administrative expenses were $1.194 million for Q3 2026, compared to $1.180 million for Q3 2025.

For the nine months ended September 30, 2026, the company disclosed total operating expenses of $9.233 million, versus $8.832 million for the same period in 2025. Research and development expenses for the nine-month period were $5.457 million, compared to $5.283 million, while general and administrative expenses were $3.776 million, compared to $3.549 million. Interest income for the nine months was $253 thousand, up from $92 thousand in the prior-year period.

The condensed balance sheet, as reported in the filing, shows total stockholders' equity of $7.652 million as of September 30, 2026, down from $11.876 million as of December 31, 2025. Additional paid-in capital stood at $95.026 million, compared to $90.265 million at year-end 2025. The company reported 3,301,175 shares of common stock outstanding as of November 4, 2026. The filing notes that no preferred stock was issued or outstanding as of either balance sheet date. The company identifies itself as a non-accelerated filer, smaller reporting company, and emerging growth company.

What Was Disclosed

Intensity Therapeutics filed its quarterly report covering the period ended September 30, 2026, disclosing a widening quarterly net loss, increased operating expenses, reduced cash balances, a growing accumulated deficit, and an increase in shares outstanding relative to December 31, 2025.